Case Report: Pansclerotic Morphea-Clinical Features, Differential Diagnoses and Modern Treatment Concepts

Pansclerotic morphea (PSM) is a rare skin disease characterized by progressive stiffening of the with or without typical superficial changes usually seen in (localized scleroderma). Standard therapy, consisting combination systemic glucocorticoids and methotrexate mycophenolate mofetil, does rarely stop progression, which may lead to severe cutaneous sclerosis secondary contractures. Little known about efficacy newer biologicals such as abatacept, fusion protein antibody against CTLA-4, tocilizumab, fully humanized IL-6R antibody, treatment this pathology. We present case an 8 years old girl unusual, skin, was eventually diagnosed pansclerotic morphea. A combined tocilizumab led good clinical response within 2 months after initiation. In paper, we discuss differential diagnoses be considered new promising option based on review literature.